优化人体血中的奇迹粒稳定性:方法开发,通过整合酶抑制剂和稳定剂进行验证
Santosh Tawari1, Ujashkumar Shah1
1Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Gujarat, India.
Biomedical chromatography : BMC
|April 4, 2025
概括
这项研究建立了一种稳定的分析方法,用于在人体血中量化mirabegron. 优化的过程确保了治疗药物监测和药理动力学研究的准确药物测量.
科学领域:
- 分析化学 分析化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 人体血中Mirabegron的稳定性对于准确量化至关重要.
- 酶和氧化降解对奇迹的分析构成挑战.
- 稳定剂和抑制剂的开发对于可靠的生物分析是必要的.
研究的目的:
- 开发和验证人类血中mirabegron的稳定性指示分析方法.
- 评估各种抑制剂和稳定剂在防止mirabegron降解方面的有效性.
- 确保该方法适用于生物等价性测试,治疗药物监测和药理动力学研究.
主要方法:
- 样品的准备涉及使用Strata-X弹进行固体相提取 (SPE).
- 在C18 Kromasil柱上优化了染色学分离,使用了氨酸盐和乙尼铁移动相.
- 检测是使用电喷离子化 (ESI) 在积极模式和多重反应监测 (MRM) 进行的.
主要成果:
- 该方法显示了高精度 (95.67%102.85%) 和精度 (0.52%2.31%).
- 在0.100到102.496 ng/mL的范围内建立了线性.
- 验证的方法需要最小的血体积 (100μL),运行时间短 (3分钟),并实现高回收率 (92.93%).
结论:
- 成功开发了一种针对人体血中mirabegron稳定性的强大而有效的分析方法.
- 该方法的稳定性,速度和最小样本要求使其非常适合临床应用.
- 这种验证的测定方法适用于生物等价性测试,治疗药物监测和药理动力学研究.
相关概念视频
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
159
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
159
Factors Affecting Drug Biotransformation: Biological
85
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
85
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
52
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
52
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
21
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
21
Factors Influencing Drug Absorption: Presystemic Elimination
162
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
162


